Hyperion DeFi, Inc. (HYPD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hyperion DeFi, Inc. (HYPD) trades at $2.72 with AI Score 18/100 (Grade F). Hyperion DeFi, Inc. is pivoting from ophthalmic drug delivery to a cryptocurrency treasury, operating a validator and engaging in DeFi staking. Market cap: $13.6M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 10, 2026Analyst Coverage for HYPD: HYPD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HYPD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HYPD: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Hyperion DeFi, Inc. (HYPD) Healthcare & Pipeline Overview
Hyperion DeFi, Inc., a U.S.-based healthcare company, is transitioning to a cryptocurrency treasury denominated in HYPE tokens, while continuing development of its Optejet UFD™ for eye care and operating a validator on the Hyperliquid blockchain. The company is also involved in DeFi staking strategies.
What Is the Investment Thesis for HYPD?
Hyperion DeFi, Inc. presents a unique investment proposition due to its hybrid business model, combining ophthalmic technology development with cryptocurrency treasury management and DeFi activities. The company's pivot towards a cryptocurrency treasury denominated in HYPE tokens introduces both opportunities and risks. Key value drivers include the potential appreciation of HYPE tokens, revenue generation from validator operations, and returns from DeFi staking strategies. The ongoing development of Optejet UFD™ represents a potential long-term value driver, contingent on successful clinical trials and regulatory approvals. However, the company's high beta of 2.63 suggests significant volatility. The negative profit margin of -5570.6% indicates substantial losses, requiring careful monitoring of cash flow and capital resources. The success of Hyperion DeFi hinges on its ability to effectively manage its cryptocurrency treasury, navigate the regulatory landscape of DeFi, and advance the development of its ophthalmic technology.
Based on FMP financials and quantitative analysis
HYPD Key Highlights
- Market capitalization of $13.6M, reflecting its small-cap status.
- Gross margin of 53.4%, indicating potential for profitability in its core operations.
- Profit margin of -5570.6%, highlighting significant losses and the need for improved financial performance.
- Beta of 2.63, indicating high volatility compared to the market.
- No dividend yield, as the company is currently reinvesting earnings for growth.
Who Are HYPD's Competitors?
HYPD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVR AlloVir, Inc. | $9.81 | +4.14% | $49.5M | 46 |
| JNJ Johnson & Johnson | $248.82 | -1.67% | $599B | 91 |
| PFE Pfizer Inc. | $24.86 | +0.44% | $142B | 66 |
| CNVIF Conavi Medical Corp. | $0.15 | -5.64% | $12.9M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.08 | -0.24% | $15.4M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.22 | +2.14% | $20.9M | 73 |
| PLSM PLSM | $3.51 | -8.12% | $22.8M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HYPD's Key Strengths?
- Innovative ophthalmic drug delivery technology (Optejet UFD™).
- First-mover advantage in cryptocurrency treasury management.
- Expertise in both healthcare and decentralized finance.
- Established validator node on the Hyperliquid blockchain.
What Are HYPD's Weaknesses?
- Negative profit margin and reliance on external funding.
- High beta and volatility.
- Limited track record in cryptocurrency treasury management.
- Regulatory uncertainty surrounding DeFi activities.
What Could Drive HYPD Stock Higher?
- Potential regulatory approvals for Optejet UFD™.
- Expansion of cryptocurrency treasury and DeFi staking activities.
- Development and enhancement of the validator node on the Hyperliquid blockchain.
What Are the Key Risks for HYPD?
- Financial-distress signal — its Altman Z-Score of -5.33 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-63.5%) — the business is not currently generating profit on shareholder capital.
- Regulatory risks associated with cryptocurrency and DeFi.
- Volatility in cryptocurrency markets.
- Competition from established pharmaceutical companies.
- Negative profit margin and reliance on external funding.
What Are the Growth Opportunities for HYPD?
- Expansion of Cryptocurrency Treasury: Hyperion DeFi has the opportunity to increase its cryptocurrency treasury by acquiring additional HYPE tokens and other digital assets. The company can leverage its expertise in DeFi to generate returns from its cryptocurrency holdings through staking, lending, and other yield-generating activities. Timeline: Ongoing.
- Validator Operations: Operating a validator node on the Hyperliquid blockchain presents a growth opportunity for Hyperion DeFi. As the Hyperliquid blockchain gains adoption, the demand for validator services is expected to increase. Hyperion DeFi can attract more users to its validator node by offering competitive rewards and ensuring high uptime and security. The validator market is estimated to be worth billions of dollars. Timeline: Ongoing.
- DeFi Staking Strategies: Hyperion DeFi can expand its DeFi staking strategies by participating in various DeFi protocols and platforms. By staking its cryptocurrency holdings, the company can earn rewards and generate passive income. The DeFi staking market is rapidly growing, with billions of dollars locked in staking contracts. Hyperion DeFi can diversify its staking portfolio to mitigate risk and maximize returns. Timeline: Ongoing.
- Optejet UFD™ Development: The ongoing development of Optejet UFD™ represents a significant growth opportunity for Hyperion DeFi. If the technology proves to be safe and effective, it could disrupt the ophthalmic drug delivery market. The global ophthalmic drug delivery market is estimated to be worth billions of dollars. Hyperion DeFi can partner with pharmaceutical companies to commercialize Optejet UFD™ and expand its market reach. Timeline: Ongoing.
- Strategic Partnerships: Hyperion DeFi can pursue strategic partnerships with other companies in the healthcare and DeFi industries. Partnerships with pharmaceutical companies can accelerate the development and commercialization of Optejet UFD™. Collaborations with DeFi projects can enhance the company's cryptocurrency treasury management and staking strategies. Strategic partnerships can provide access to new markets, technologies, and expertise. Timeline: Ongoing.
What Opportunities Does HYPD Have?
- Expansion of cryptocurrency treasury and DeFi staking strategies.
- Commercialization of Optejet UFD™.
- Strategic partnerships with pharmaceutical companies and DeFi projects.
- Growth of the cryptocurrency and DeFi markets.
What Threats Does HYPD Face?
- Competition from established pharmaceutical companies.
- Regulatory risks associated with cryptocurrency and DeFi.
- Volatility in cryptocurrency markets.
- Technological disruptions in ophthalmic drug delivery.
What Are HYPD's Competitive Advantages?
- First-mover advantage as the first Nasdaq-listed U.S. company with a cryptocurrency treasury.
- Proprietary ophthalmic drug delivery technology (Optejet UFD™).
- Expertise in both healthcare and decentralized finance.
- Established validator node on the Hyperliquid blockchain.
What Does HYPD Do?
Hyperion DeFi, Inc., formerly focused on ophthalmic drug delivery technology, is undergoing a strategic shift towards becoming the first Nasdaq-listed U.S. company with a cryptocurrency treasury. The company's initial focus was on the development and commercialization of the Optejet device, a micro-volume delivery system designed for ophthalmic applications. Founded with the goal of improving drug delivery to the eye, Hyperion aimed to address challenges associated with traditional eye drops, such as poor bioavailability and patient compliance. Now, Hyperion DeFi is pivoting to embrace decentralized finance (DeFi) by establishing a cryptocurrency treasury denominated in HYPE tokens from the Hyperliquid blockchain. In addition to its cryptocurrency initiatives, Hyperion DeFi operates a validator node called “Kinetiq × Hyperion” on the Hyperliquid blockchain, contributing to the network's security and governance. The company also continues to engage in DeFi staking strategies, seeking to generate returns from its cryptocurrency holdings. Simultaneously, Hyperion DeFi is continuing the development of Optejet UFD™, its innovative eye care technology. This dual focus reflects the company's ambition to bridge the gap between traditional healthcare and the emerging world of decentralized finance.
What Products and Services Does HYPD Offer?
- Develops ophthalmic drug delivery technology (Optejet).
- Manages a cryptocurrency treasury denominated in HYPE tokens.
- Operates a validator node on the Hyperliquid blockchain.
- Engages in DeFi staking strategies.
- Seeks to bridge the gap between traditional healthcare and decentralized finance.
- Aims to improve drug delivery to the eye.
How Does HYPD Make Money?
- Generates revenue from validator operations on the Hyperliquid blockchain.
- Earns returns from DeFi staking strategies.
- Potential future revenue from commercialization of Optejet UFD™.
- Manages a cryptocurrency treasury with potential for appreciation in value.
What Industry Does HYPD Operate In?
Hyperion DeFi, Inc. operates at the intersection of the healthcare and decentralized finance (DeFi) industries. The healthcare industry is characterized by innovation in drug delivery systems and a growing emphasis on patient compliance. The DeFi industry is rapidly evolving, with increasing adoption of cryptocurrencies and decentralized applications. Hyperion DeFi's strategic pivot reflects a trend of companies exploring opportunities in the DeFi space. However, the company faces competition from established pharmaceutical companies and emerging DeFi projects. The success of Hyperion DeFi will depend on its ability to navigate the regulatory landscape, manage risk, and differentiate itself in a competitive market.
Who Are HYPD's Key Customers?
- Patients requiring ophthalmic drug delivery.
- Users of the Hyperliquid blockchain.
- Participants in DeFi protocols and platforms.
- Pharmaceutical companies (potential partners).
How Hyperion DeFi, Inc. Is Valued
Hyperion DeFi, Inc. carries a market capitalization of $13.6M, placing it in the micro-cap category. Relative to its peer group, HYPD's quantitative score of 18/100 is below the peer average of 66/100.
Company Profile
Hyperion DeFi, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in New York, US. The company is led by CEO Hyunsu Jung. HYPD has traded publicly since 2025.
ROE -64%Key Financial Metrics
Return on equity for Hyperion DeFi, Inc. stands at -63.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.1%, showing how much profit it generates from its asset base. A current ratio of 1.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -103.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Hyperion DeFi, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.33 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Hyperion DeFi, Inc. revenue of about $7.0M for fiscal 2026, with EPS near $0.79.
HYPD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insider buying activity has increased, indicating confidence from leadership in the company's future.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments.
- Recent partnerships in the DeFi space have strengthened Hyperion's market position and visibility.
- The overall growth of the decentralized finance sector has created a favorable environment for Hyperion's offerings.
Bear Case
- Concerns over regulatory scrutiny in the DeFi space could impact operational flexibility and growth prospects.
- Negative sentiment from some community members regarding project execution and transparency issues.
- Recent market volatility has led to skepticism about the sustainability of DeFi projects like Hyperion.
- Competitors are gaining traction, which may dilute Hyperion's market share and investor interest.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HYPD Latest News
-
Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga · Jun 9, 2026
-
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
benzinga · Jun 8, 2026
-
Earnings Scheduled For May 14, 2026
benzinga · May 14, 2026
HYPD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HYPD.
Price Targets
Wall Street price target analysis for HYPD.
HYPD MoonshotScore
What does this score mean?
The MoonshotScore rates HYPD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Hyunsu Jung
CEO
Hyunsu Jung is the CEO of Hyperion DeFi, Inc., leading a team of 13 employees. His background includes experience in managing and growing technology-focused ventures. He is responsible for guiding the company's strategic direction, overseeing operations, and driving innovation. Mr. Jung's expertise spans both the healthcare and financial technology sectors, positioning him well to lead Hyperion DeFi through its transition.
Track Record: Under Hyunsu Jung's leadership, Hyperion DeFi has initiated its strategic pivot towards cryptocurrency treasury management and DeFi activities. He has overseen the development of the company's validator node on the Hyperliquid blockchain and the continued development of Optejet UFD™. His focus is on building a sustainable business model that leverages the synergies between healthcare and decentralized finance.
Hyperion DeFi, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for HYPD?
HYPD holds an AI Score of 18/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Hyperion DeFi, Inc. is pivoting from ophthalmic drug delivery to a cryptocurrency treasury, operating a validator and engaging in DeFi staking. The company is also developing its Optejet UFD™ …
What does Hyperion DeFi, Inc. do?
Hyperion DeFi, Inc. is a U.S.-based company that is pivoting from ophthalmic drug delivery technology to managing a cryptocurrency treasury denominated in HYPE tokens. The company operates a validator node on the Hyperliquid blockchain and engages in DeFi staking strategies. Simultaneously, Hyperion DeFi is continuing the development of Optejet UFD™, its innovative eye care technology.
What do analysts say about HYPD stock?
As of 2026-05-10, analyst coverage of Hyperion DeFi, Inc. (HYPD) is limited, likely due to its small market capitalization and recent strategic shift. Key valuation metrics, such as price-to-earnings ratio, are not meaningful due to the company's negative profit margin.
What are the main risks for HYPD?
Hyperion DeFi, Inc. faces several key risks. Regulatory uncertainty surrounding cryptocurrency and DeFi activities poses a significant challenge. Volatility in cryptocurrency markets could negatively impact the value of its treasury. Competition from established pharmaceutical companies could hinder the commercialization of Optejet UFD™. The company's negative profit margin and reliance on external funding raise concerns about its financial sustainability. Investors should carefully assess these risks before investing in HYPD.
What are the key growth opportunities for HYPD in healthcare?
Hyperion DeFi, Inc.'s primary growth opportunity in healthcare lies in the successful development and commercialization of its Optejet UFD™ technology. This innovative drug delivery system has the potential to improve patient compliance and enhance the efficacy of ophthalmic treatments. Expansion into new therapeutic areas, such as glaucoma and macular degeneration, could further drive growth.
How does Hyperion DeFi, Inc.'s cryptocurrency treasury impact its financial stability?
Hyperion DeFi, Inc.'s cryptocurrency treasury introduces both opportunities and risks to its financial stability. The potential appreciation of HYPE tokens could significantly enhance the company's assets and improve its financial position. However, the volatility of cryptocurrency markets could also lead to substantial losses. Effective management of the cryptocurrency treasury is crucial to mitigating risk and ensuring financial stability.
What are the key factors to evaluate for HYPD?
Hyperion DeFi, Inc. (HYPD) holds an AI score of 18/100 (low). Not financial advice.
How frequently does HYPD data refresh on this page?
HYPD's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HYPD's recent stock price performance?
Hyperion DeFi, Inc. (HYPD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative ophthalmic drug delivery technology (Optejet UFD™). See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to small market cap and recent strategic shift.
- High volatility associated with cryptocurrency and DeFi activities.
- Financial data based on available information and may be subject to change.